









Markets
/
Stocks
/
nasdaq-fdmt
/

4D Molecular Therapeutics Inc

FDMT

8.990USD

+0.600+7.15%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

420.47MMarket Cap

LossP/E TTM



4D Molecular Therapeutics Inc

8.990

+0.600+7.15%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of 4D Molecular Therapeutics Inc

Currency: USD Updated: 2026-02-05

Key Insights

4D Molecular Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 51 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 33.11.In the medium term, the stock price is expected to trend down.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

4D Molecular Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

51 / 392

Overall Ranking

166 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

4D Molecular Therapeutics Inc Highlights

StrengthsRisks

4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.

Growing

The company is in a growing phase, with the latest annual income totaling USD 37.00K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 37.00K.

Overvalued

The company’s latest PE is -2.24, at a high 3-year percentile range.

Held by Paul Tudor Jones

Star Investor Paul Tudor Jones holds 25.77K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.89.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

33.111

Target Price

+261.87%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-05

The current financial score of 4D Molecular Therapeutics Inc is 7.11, ranking 154 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 90.00K, representing a year-over-year increase of 2900.00%, while its net profit experienced a year-over-year increase of 29.73%.

Score

Industry at a Glance

Previous score

7.11

Change



Financials

7.16

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.83

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.08

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.47

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

4D Molecular Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-05

The current valuation score of 4D Molecular Therapeutics Inc is 7.76, ranking 81 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.24, which is -64.77% below the recent high of -0.79 and -522.24% above the recent low of -13.92.

Score

Industry at a Glance

Previous score

7.76

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 51/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-05

The current earnings forecast score of 4D Molecular Therapeutics Inc is 8.18, ranking 155 out of 392 in the Biotechnology & Medical Research industry. The average price target is 33.00, with a high of 45.00 and a low of 17.00.

Score

Industry at a Glance

Previous score

8.18

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

33.111

Target Price

+294.65%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

4D Molecular Therapeutics Inc

FDMT

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-05

The current price momentum score of 4D Molecular Therapeutics Inc is 6.67, ranking 145 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 9.74 and the support level at 7.09, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.39

Change

-1.72

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.299

Neutral

RSI(14)

54.384

Neutral

STOCH(KDJ)(9,3,3)

58.233

Sell

ATR(14)

0.610

High Vlolatility

CCI(14)

37.836

Neutral

Williams %R

31.791

Buy

TRIX(12,20)

0.338

Sell

StochRSI(14)

43.497

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

9.062

Sell

MA10

8.820

Buy

MA20

8.317

Buy

MA50

8.969

Buy

MA100

9.368

Sell

MA200

7.047

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-05

The current institutional shareholding score of 4D Molecular Therapeutics Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 123.08%, representing a quarter-over-quarter decrease of 0.59%. The largest institutional shareholder is The Vanguard, holding a total of 3.09M shares, representing 6.06% of shares outstanding, with 1.89% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BVF Partners L.P.

4.63M

RA Capital Management, LP

4.56M

Goldman Sachs & Company, Inc.

3.71M

-0.86%

Novo Holdings A/S

3.17M

+58.75%

The Vanguard Group, Inc.

Star Investors

2.58M

-5.90%

BlackRock Institutional Trust Company, N.A.

3.01M

-3.49%

Janus Henderson Investors

1.75M

-0.06%

Kirn (David)

1.66M

-0.02%

Federated MDTA LLC

1.56M

-5.75%

Millennium Management LLC

1.15M

-22.53%

Risk Assessment

Currency: USD Updated: 2026-02-05

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of 4D Molecular Therapeutics Inc is 3.42, ranking 145 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 3.00. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.